An interventional study of 3T and 7T UHF MRI in Unruptured Intracranial Aneurysms, Subarachnoid Hemorrhage (SAH) and 7 TESLA, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Subarachnoid Hemorrhage with a site in Switzerland — 5 open to participants now, 5 under way, none of them phase 3. Subarachnoid Hemorrhage · Switzerland.
Among the 25 studies in Subarachnoid Hemorrhage with a site in Switzerland, this one is the 8th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2024, is one of 11 with no phase, and was the 25th registered.
512 studies on the registry are indexed under Subarachnoid Hemorrhage; 130 are open to participants now.
Browse Subarachnoid Hemorrhage studies →5 of the 25 studies in Subarachnoid Hemorrhage with a site in Switzerland are open now. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 30–60 · Healthy volunteers
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 16+
University Hospital, Geneva · Sites in Switzerland
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 90 Subarachnoid Hemorrhage studies recruiting now, 56 (62%) set no upper age limit and 5 (6%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 58 across 265 interventional studies indexed under Subarachnoid Hemorrhage.
Median enrollment 95 across the 16 interventional studies, 198 across the 9 observational. Of the 19 that completed or were terminated, 2 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 25 have an industry lead sponsor. The 10 most frequent:
Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.
Insel Gruppe AG, University Hospital Bern has 8 studies filed under Subarachnoid Hemorrhage — fewer than ten, so there is no comparison to draw.
2 of the studies in Subarachnoid Hemorrhage with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04043598Insel Gruppe AG, University Hospital BernCrystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage | 2027-07 |
| NCT07938775Insel Gruppe AG, University Hospital BernSwiss Pilot Screening Study for Unruptured Intracranial Aneurysms to Prevent Subarachnoid Hemorrhage in Smokers | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies in Subarachnoid Hemorrhage with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Approximately 275'000 people in Switzerland harbor an unruptured intracranial aneurysm (UIA). Rupture leads to subarachnoid hemorrhage, which is associated with high morbidity and mortality and causes 25% of all cerebrovascular-related deaths. UIAs cause a relevant healthcare burden, which is increasing due to the extensive use of neuroimaging. They pose a challenge to both patients and physicians: Patients have to live with the diagnosis of an aneurysm that can cause a rupture with severe consequences. Physicians have to judge whether the risks of preventive occlusion are lower than those of natural history. Management consists of observation with follow-up imaging or preventive aneurysm occlusion weighing up the risk of natural history against the risk of treatment. Estimating rupture risks of UIAs in an individual patient is the crucial step in clinical decision-making.
Older studies suggested that small UIA (\<7mm) have a negligible rupture risk and most incidental UIAs are small. Following this logic, most patients with UIA do not require preventive treatment. However, 70-80% of patients presenting with subarachnoid hemorrhage carry aneurysms \<7 mm in size, leading to the so-called "aneurysm-rupture paradox". Newer evidence shows that UIAs have a heterogenous natural history: They can either form and remain stable for a long time or present an unstable course, entertained by wall inflammation, leading to aneurysm growth, and ultimately rupture.
The main clinical challenge in UIA is to correctly identify aneurysms that have an unstable course out of the increasing amount of incidentally detected UIAs and offer preventive treatment to these selected patients. Growth during follow-up, irregular aneurysm shape, hypertension, and smoking are currently used as main surrogate parameters to predict an unstable UIA.
Ultra-high field 7 Tesla MRI (UHF 7T MRI) has become clinically available as a new imaging modality. Due to the higher field strength, UHF 7T MRI enables imaging with an increased signal-to-noise ratio resulting in significantly improved vessel wall imaging and spatial resolution to detect AWE and morphological changes with high precision. With these properties, UHF 7T MRI has the potential to overcome current limitations of vessel wall imaging in 3T MRI by providing information on AWE with increased specificity omitting the high false positive rates that make AWE as a biomarker in 3T MRI not useful.
After obtaining the signed informed consent and inclusion in the study, demographics will be assessed. The 3T MRI and 7T UHF MRI follow-up examination will be scheduled as a next step, and the appointment will be communicated to the participant. The timing of the 3T + 7T UHF MRI examination is not determined by the date of enrolment but by the timing of the baseline examination and must be no later than 12±1 months after that.
The exam will take place at the Translational Imaging center in Sitem-insel. Before the MRI examination, participants are asked to provide information on risk factors for UIA and medication history via a questionnaire. For the MRI examination, a 3 T scanner will be used with a standard head coil provided by the the MR-vendor and a 7 T whole-body MRI scanner equipped with a 1-channel transmit and 32-channel receive head coil. The 7T protocoll will comprose arterial ToF angiography and vessel wall imaging sequences (T1 SPACE and T1 SE dark blood). The acquisition time is approximately 44 minutes. The 3T examination will be performed according to the clinical standard protocol. After the examination, participants can go directly home and no further examinations will be performed at this appointment.
According to the standard of care at our institutions, all follow-up examinations of patients with UIA, who have been assigned to observation with MRI, will be discussed at the interdisciplinary aneurysm board. Within 4-8 weeks after the 3T + 7T UHF MRI examination, a chart review of the board decision and outpatient visits will be performed to determine whether management changed from observation to intervention. Furthermore, the occurrence of subarachnoid hemorrhage during the study period will be recorded if applicable.
Approximately 275'000 people in Switzerland harbor an unruptured intracranial aneurysm (UIA). Rupture leads to subarachnoid hemorrhage, which is associated with high morbidity and mortality and causes 25% of all cerebrovascular-related deaths. UIAs cause a relevant healthcare burden, which is increasing due to the extensive use of neuroimaging. They pose a challenge to both patients and physicians: Patients have to live with the diagnosis of an aneurysm that can cause a rupture with severe consequences. Physicians have to judge whether the risks of preventive occlusion are lower than those of natural history. Management consists of observation with follow-up imaging or preventive aneurysm occlusion weighing up the risk of natural history against the risk of treatment. Estimating rupture risks of UIAs in an individual patient is the crucial step in clinical decision-making.
Older studies suggested that small UIA (\<7mm) have a negligible rupture risk and most incidental UIAs are small. Following this logic, most patients with UIA do not require preventive treatment. However, 70-80% of patients presenting with subarachnoid hemorrhage carry aneurysms \<7 mm in size, leading to the so-called "aneurysm-rupture paradox". Newer evidence shows that UIAs have a heterogenous natural history: They can either form and remain stable for a long time or present an unstable course, entertained by wall inflammation, leading to aneurysm growth, and ultimately rupture.
The main clinical challenge in UIA is to correctly identify aneurysms that have an unstable course out of the increasing amount of incidentally detected UIAs and offer preventive treatment to these selected patients. Growth during follow-up, irregular aneurysm shape, hypertension, and smoking are currently used as main surrogate parameters to predict an unstable UIA. However, these parameters are only indirect since they are either consequences of wall inflammation (growth, irregular shape) or are risk factors that increase the probability of it (smoking, hypertension).
In contrast to this, aneurysm wall enhancement (AWE) is a possible direct biomarker that can visualize wall inflammation and, therefore, aneurysm instability. Studies investigating AWE and aneurysm instability showed a reasonably high sensitivity for prediction of aneurysm growth but are limited by low specificity and a high false-positive rate since AWE was present in 30-40% of aneurysms that were stable during follow-up. Therefore use of AWE as an indicator for aneurysm instability has not yet made the critical step as a reliable biomarker in the decision-making process, despite its high potential. Consequently, recent UIA guidelines from the European Stroke Organization highly recommend further clinical studies on AWE.
Ultra-high field 7 Tesla MRI (UHF 7T MRI) has become clinically available as a new imaging modality. Due to the higher field strength, UHF 7T MRI enables imaging with an increased signal-to-noise ratio resulting in significantly improved vessel wall imaging and spatial resolution to detect AWE and morphological changes with high precision. With these properties, UHF 7T MRI has the potential to overcome current limitations of vessel wall imaging in 3T MRI by providing information on AWE with increased specificity omitting the high false positive rates that make AWE as a biomarker in 3T MRI not useful. However, data analyzing AWE with increased precision in UHF 7T MRI in a large cohort are missing.
The Translation Imaging Center Bern (TIC) at sitem-insel provides a unique imaging infrastructure in Switzerland and worldwide with a clinically approved latest generation UHF 7T MRI system and 3T MRI allowing direct comparing of findings at 3T and 7T.
After obtaining the signed informed consent and inclusion in the study, demographics will be assessed. The 3T MRI and 7T UHF MRI follow-up examination will be scheduled as a next step, and the appointment will be communicated to the participant. The timing of the 3T + 7T UHF MRI examination is not determined by the date of enrolment but by the timing of the baseline examination and must be no later than 12±1 months after that. Before the MRI is performed, a urine pregnancy test will be performed for all woman with childbearing potential.
The exam will take place at the Translational Imaging center in Sitem-insel. Before the MRI examination, participants are asked to provide information on risk factors for UIA and medication history via a questionnaire. For the MRI examination, a 3 T scanner (MAGNETOM Prisma, Siemens Healthcare) will be used with a standard head coil provided by the the MR-vendor and a 7 T whole-body MRI scanner (MAGNETOM Terra, clinical mode, Siemens Healthcare, Erlangen, Germany) equipped with a 1-channel transmit and 32-channel receive head coil (Nova Medical, Wilmington, MA, USA). Only CE approved sequences will be accuired. The 7T protocoll will comprose arterial ToF angiography and vessel wall imaging sequences (T1 SPACE and T1 SE dark blood). The acquisition time is approximately 44 minutes. The 3T examination will be performed according to the clinical standard protocoll. After the examination, participants can go directly home and no further examinations will be performed at this appointment.
According to the standard of care at our institutions, all follow-up examinations of patients with UIA, who have been assigned to observation with MRI, will be discussed at the interdisciplinary aneurysm board. Within 4-8 weeks after the 3T + 7T UHF MRI examination, a chart review of the board decision and outpatient visits will be performed to determine whether management changed from observation to intervention. Furthermore, the occurrence of subarachnoid hemorrhage during the study period will be recorded if applicable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
aneurysm wall enhancement, aneurysm growth, and changes in aneurysm morphology in a simoultaneous 3T (standard clinical follow-up) and UHF 7T MRI
Device: 3T and 7T UHF MRI
After obtaining the signed informed consent and inclusion in the study, demographics will be assessed. The timing of the 3T + 7T UHF MRI examination is not determined by the date of enrolment but by the timing of the baseline examination and must be no later than 12±1 months after that. The exam will take place at the Translational Imaging center in Sitem-insel. Before the MRI examination, participants are asked to provide information on risk factors for UIA and medication history via a questionnaire. For the MRI examination, we will use a 3 T scanner with a standard head coil provided by the the MR-vendor and a 7 T whole-body MRI scanner equipped with a 1-channel transmit and 32-channel receive head coil. The 7T protocoll will comprose arterial ToF angiography and vessel wall imaging sequences. Within 4-8 weeks after the 3T + 7T UHF MRI examination, a chart review of the booard decision and outpatient visits will be performed to determine whether management changed from observation.
Correlation between aneurysm wall enhancement (AWE) characteristics and aneurysm growth or change of morphology compared to standard follow-up
We will assess AWE, aneurysm growth, and changes in aneurysm morphology in a simoultaneous 3T (standard clinical follow-up) and UHF 7T MRI after 12±1 months of follow-up. AWE is categorized as none, focal, circumferential \<1mm, or circumferential \>1mm. Aneurysm growth is defined as an increase in diameter in any direction by ≥1mm and categorized as absent or present. Morphological change is defined as any new occurrence of irregular shape (such as lobulation, blep, aneurysm wall protrusions) and is categorized as absent or present.
Time frame: 12 months after baseline MRI
aneurysm wall enhancement in UHF 7T MRI and standard clinical follow-up with 3T MRI after 12 months of Follow UP
Time frame: 12 months Follow UP
aneurysm growth in UHF 7T MRI and standard clinical follow-up with 3T MRI after 12 months of follow-up.
Time frame: 12 months Follow UP
changed morphology in UHF 7T MRI and standard clinical follow-up with 3T MRI after 12 months of follow-up
Time frame: 12 months Follow UP
aneurysm wall enhancement
Time frame: baseline
aneurysm size
Time frame: baseline
aneurysm morphology
Time frame: baseline
Risk factors
Time frame: baseline
medications
Time frame: baseline
Focal aneurysm wall enhancement patterns in UHT 7T MRI with 3D mapping of the aneurysm dome
Time frame: 12 months Follow UP
Incidence of subarachnoid hemorrhage during follow-up
Time frame: 12 months Follow UP
Incidence of aneurysm growth during follow-up
Time frame: 12 months Follow UP
Change of management from observation toward intervention after the follow-up visit
Time frame: 12 months Follow UP
Radiomics of the aneurysm dome
Time frame: 12 months Follow UP
Started Dec 2024 (actual). Primary completion is estimated for Aug 2028, 44 months after the start.
Of 58 non-industry interventional studies with no phase under Subarachnoid Hemorrhage, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 69. This study's planned 44 months is above that.
Counting every sponsor, half of 68 studies reached it within 32 months; a quarter within 20 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insel Gruppe AG, University Hospital Bern →